These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 9164935

  • 1. TNF receptor p55 controls early acute graft-versus-host disease.
    Speiser DE, Bachmann MF, Frick TW, McKall-Faienza K, Griffiths E, Pfeffer K, Mak TW, Ohashi PS.
    J Immunol; 1997 Jun 01; 158(11):5185-90. PubMed ID: 9164935
    [Abstract] [Full Text] [Related]

  • 2. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL.
    J Clin Invest; 1999 Aug 01; 104(4):459-67. PubMed ID: 10449438
    [Abstract] [Full Text] [Related]

  • 3. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB.
    Biol Blood Marrow Transplant; 2005 Aug 01; 11(8):576-86. PubMed ID: 16041307
    [Abstract] [Full Text] [Related]

  • 4. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Aug 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 5. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS.
    Nat Med; 2003 Sep 01; 9(9):1144-50. PubMed ID: 12925844
    [Abstract] [Full Text] [Related]

  • 6. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 7. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug 01; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 8. Intermediate TCR cells can induce graft-versus-host disease after allogeneic bone marrow transplantation.
    Weerasinghe A, Kawamura T, Moroda T, Seki S, Watanabe H, Abo T.
    Cell Immunol; 1998 Apr 10; 185(1):14-29. PubMed ID: 9636679
    [Abstract] [Full Text] [Related]

  • 9. T-cell P/E-selectin ligand alpha(1,3)fucosylation is not required for graft-vs-host disease induction.
    Eom HS, Rubio MT, Means TK, Luster AD, Sykes M.
    Exp Hematol; 2005 Dec 10; 33(12):1564-73. PubMed ID: 16338500
    [Abstract] [Full Text] [Related]

  • 10. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC, Friedman TM, Murphy GF, Korngold R.
    Biol Blood Marrow Transplant; 2004 Feb 10; 10(2):91-105. PubMed ID: 14750075
    [Abstract] [Full Text] [Related]

  • 11. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
    Welniak LA, Wang Z, Sun K, Kuziel W, Anver MR, Blazar BR, Murphy WJ.
    Exp Hematol; 2004 Mar 10; 32(3):318-24. PubMed ID: 15003318
    [Abstract] [Full Text] [Related]

  • 12. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 10; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation.
    Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG.
    Transplantation; 2003 Dec 27; 76(12):1742-9. PubMed ID: 14688526
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers.
    Eyrich M, Burger G, Marquardt K, Budach W, Schilbach K, Niethammer D, Schlegel PG.
    Biol Blood Marrow Transplant; 2005 May 27; 11(5):371-82. PubMed ID: 15846291
    [Abstract] [Full Text] [Related]

  • 20. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease.
    Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG.
    J Clin Invest; 2002 May 27; 109(10):1335-44. PubMed ID: 12021249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.